Biomarkers in Cancer

In our research group, we are conducting biomarker research (diagnostic, predictive and prognostic) in various solid tumors. Herein, we focus on head and neck carcinoma, as well as urogenitourinary cancers:

• Search for Novel Predictive Biomarkers for Immunotherapy in Head and Neck Carcinoma and Urothelial carcinoma
• Use of N-glycosylation as Novel Diagnostic and Prognostic Biomarker in Prostate Cancer
• Search for Early Biomarkers Predicting Kidney Damage and Therapy Response in Patients with Renal Cell Carcinoma Treated with TKIs
• Search for Brain Metastatic Prognostic Markers in Various Solid Tumors
• Search for the Impact of Chemotherapy on the Immune Profile in Urothelial Carcinoma
• Biomarker Research for Response Prediction of TKI Treatment in Clear-Cell Renal Cell Carcinoma

Projects (current and recently finalized)

• Glycosylation of Prostate-Specific Antigen and Possible Diagnostic Applications

• Search for Early Biomarkers Predicting Kidney Damage and Therapy Response in Patients with Renal Cell Carcinoma

• Search for Brain Metastatic Prognostic Markers in Various Solid Tumors

• Biomarker Research in Solid Carcinoma: Predicting Toxicity and Response Prediction during Treatment with Immune Checkpoint Inhibitors

• Search for the Impact of Chemotherapy on the Immune Profile in Urothelial Carcinoma

• Biomarker Research for Response Prediction of TKI Treatment in Clear-Cell Renal Cell Carcinoma

Infrastructure and techniques

Our research group has close collaborations with several departments (Dept. Clinical Chemistry – Ghent University Hospital, Dept. Pathology – Ghent University Hospital, Center for Medical Biotechnology – VIB, Ghent University) who have all needed equipment to perform all experiments.

Staff

• Sylvie Rottey, MD, PhD
• Brant Delafontaine, MD
• Daan De Maeseneer, MD
• Stijn De Keukeleire, MD

Contact

Sylvie Rottey; MD, PhD

Drug Research Unit Ghent, Entrance 52 – Route 5210

Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium